Completed PHASE3 INTERVENTIONAL NCT00305500

Tolerability and Efficacy of High Dose Escitalopram for the Treatment of Obsessive-Compulsive Disorder (OCD)

Phase III Open Study of High Dose Escitalopram for the Treatment of Obsessive-Compulsive Disorder in Adults

Sponsor: Abarbanel Mental Health Center

Conditions Obsessive-Compulsive Disorder

Updated 6 times since 2017 Last updated: Jul 25, 2006 Started: Mar 31, 2006 Completion: Dec 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Obsessive-Compulsive Disorder, this trial is completed. The trial is conducted by Abarbanel Mental Health Center and has accumulated 6 data snapshots since 2006. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Mar 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Abarbanel Mental Health Center

Data source: Abarbanel Mental Health Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bat Yam, Israel